ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIPGet Rating) have received a consensus rating of “Hold” from the six ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $58.50.

Several research firms have commented on ANIP. TheStreet lowered shares of ANI Pharmaceuticals from a “c-” rating to a “d+” rating in a research report on Wednesday, March 30th. Zacks Investment Research raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday. StockNews.com downgraded shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, April 27th. Raymond James reduced their target price on shares of ANI Pharmaceuticals from $65.00 to $47.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 16th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of ANI Pharmaceuticals in a report on Wednesday, March 16th.

Shares of ANI Pharmaceuticals stock opened at $29.92 on Friday. The company has a fifty day moving average of $29.23 and a 200-day moving average of $37.98. ANI Pharmaceuticals has a 52-week low of $22.73 and a 52-week high of $60.23. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.74 and a current ratio of 3.79. The stock has a market capitalization of $516.78 million, a price-to-earnings ratio of -6.60 and a beta of 1.06.

ANI Pharmaceuticals (NASDAQ:ANIPGet Rating) last released its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of $0.09 by ($0.21). ANI Pharmaceuticals had a negative net margin of 27.78% and a positive return on equity of 6.66%. During the same period in the previous year, the firm earned $0.92 EPS. On average, equities research analysts forecast that ANI Pharmaceuticals will post 0.68 earnings per share for the current fiscal year.

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani purchased 7,224 shares of ANI Pharmaceuticals stock in a transaction on Monday, March 21st. The stock was bought at an average price of $27.69 per share, for a total transaction of $200,032.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Patrick D. Walsh purchased 5,000 shares of ANI Pharmaceuticals stock in a transaction dated Monday, March 21st. The stock was bought at an average cost of $27.76 per share, with a total value of $138,800.00. The disclosure for this purchase can be found here. Insiders acquired 17,224 shares of company stock valued at $477,083 in the last ninety days. 27.20% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. lifted its holdings in ANI Pharmaceuticals by 9.9% in the 1st quarter. BlackRock Inc. now owns 1,853,463 shares of the specialty pharmaceutical company’s stock worth $52,103,000 after purchasing an additional 166,850 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of ANI Pharmaceuticals by 8.2% during the first quarter. Vanguard Group Inc. now owns 775,299 shares of the specialty pharmaceutical company’s stock valued at $21,793,000 after acquiring an additional 58,523 shares during the period. William Blair Investment Management LLC grew its stake in ANI Pharmaceuticals by 26.5% during the first quarter. William Blair Investment Management LLC now owns 571,180 shares of the specialty pharmaceutical company’s stock worth $16,056,000 after buying an additional 119,736 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in ANI Pharmaceuticals by 17.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 456,147 shares of the specialty pharmaceutical company’s stock valued at $12,823,000 after purchasing an additional 66,843 shares in the last quarter. Finally, State Street Corp raised its holdings in shares of ANI Pharmaceuticals by 6.5% in the fourth quarter. State Street Corp now owns 437,580 shares of the specialty pharmaceutical company’s stock valued at $20,164,000 after buying an additional 26,560 shares during the last quarter. Institutional investors and hedge funds own 59.66% of the company’s stock.

About ANI Pharmaceuticals (Get Rating)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies.

Read More

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.